Arca
Skip to content
Tools
Tools

Uterine cancer

Drug research and approvals for uterine cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 707 studies of uterine cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 3 drug trials for it since 2013.

  • Recruiting worldwide: 707
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 707 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 5

  • BevacizumabUterine cervical cancer · Vascular endothelial growth factor A inhibitor
  • PembrolizumabEndometrial cancer · Programmed cell death protein 1 inhibitor
  • TopotecanUterine cervical cancer · DNA topoisomerase I inhibitor
  • DostarlimabEndometrial cancer · Programmed cell death protein 1 antagonist
  • Tisotumab vedotinUterine cervical cancer · Tubulin inhibitor

Phase 3 12 of 60

  • CisplatinUterine cervical cancer · DNA inhibitor
  • PaclitaxelUterine cervical cancer · Tubulin inhibitor
  • CarboplatinUterine cervical cancer · DNA inhibitor
  • DoxorubicinEndometrial cancer · DNA topoisomerase II alpha inhibitor
  • LetrozoleEndometrial cancer · Cytochrome P450 19A1 inhibitor
  • GemcitabineUterine cervical cancer · Ribonucleoside-diphosphate reductase RR1 inhibitor
  • CadonilimabUterine cervical cancer · Programmed cell death protein 1 inhibitor
  • DocetaxelUterine cervical cancer · Tubulin inhibitor
  • Medroxyprogesterone acetateEndometrial cancer · Progesterone receptor agonist
  • MetforminEndometrial cancer · Mitochondrial complex I (NADH dehydrogenase) inhibitor
  • NimotuzumabUterine cervical cancer · Epidermal growth factor receptor erbB1 inhibitor
  • ZimberelimabUterine cervical cancer · Programmed cell death protein 1 inhibitor

Phase 2 12 of 140

  • CamrelizumabUterine cervical cancer · Programmed cell death protein 1 antagonist
  • EverolimusEndometrial cancer · FK506-binding protein 1A inhibitor
  • ToripalimabUterine cervical cancer · Programmed cell death protein 1 antagonist
  • TislelizumabUterine cervical cancer · Programmed cell death protein 1 inhibitor
  • NiraparibEndometrial cancer · Poly [ADP-ribose] polymerase 2 inhibitor
  • SintilimabUterine cervical cancer · Programmed cell death protein 1 antagonist
  • CapecitabineUterine cervical cancer · Thymidylate synthase inhibitor
  • CetuximabUterine cervical cancer · Epidermal growth factor receptor erbB1 inhibitor
  • Mirvetuximab soravtansineEndometrial cancer · Folate receptor alpha binding agent
  • AmifostineUterine cervical cancer · Reactive metabolite scavenging agent
  • NivolumabUterine cervical cancer · Programmed cell death protein 1 inhibitor
  • BuparlisibEndometrial cancer · PI3-kinase class I inhibitor

Phase 1 or earlier 12 of 49

  • CidofovirUterine cervical cancer · Human herpesvirus 1 DNA polymerase inhibitor
  • NelfinavirUterine cervical cancer · Human immunodeficiency virus type 1 protease inhibitor
  • SS1(DSFV)-PE38Uterine cervical cancer · Mesothelin binding agent
  • Denileukin diftitoxEndometrioid cancer · Elongation factor 2 inhibitor
  • FludarabineUterine cervical cancer
  • AldesleukinUterine cervical cancer · Interleukin-2 receptor agonist
  • Trastuzumab emtansineEndometrial cancer · Receptor protein-tyrosine kinase erbB-2 binding agent
  • BosutinibUterine cervical cancer · Tyrosine-protein kinase ABL inhibitor
  • ImatinibTyrosine-protein kinase ABL inhibitor
  • SorafenibUterine cervical cancer · Serine/threonine-protein kinase RAF inhibitor
  • AnastrozoleEndometrial cancer · Cytochrome P450 19A1 inhibitor
  • MiransertibEndometrial cancer · Serine/threonine-protein kinase AKT inhibitor

How its trials ended

228 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 49 whose ending is known, 29% met their primary endpoint, 8% missed it and 63% stopped early.

  • Completed, result not reported8738%
  • Ongoing6629%
  • Status unknown2611%
  • Stopped: other or unclear157%
  • Met its primary endpoint146%
  • Stopped: enrollment or feasibility125%
  • Missed its primary endpoint42%
  • Stopped: sponsor or business decision31%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
May 30, 2024Beamion pantumor-1: a phase II, multicentre, multicohort, open label trial to evaluate the efficacy and safety of oral zongertinib (bi 1810631) for the…Zongertinib (bi 1810631)Boehringer Ingelheim (Canada) Ltd LteeOngoing
Nov 21, 2023Phase I study of the PKMYT1 inhibitor RP-6306 in combination with carboplatin and paclitaxel for the treatment of recurrent TP53 ovarian and uterine cancer…Lunresertib (RP-6306)University Health NetworkClosed
Aug 25, 2023The epoch study: phase II open labelled study investigating the use of single agent eribulin and eribulin in combination with pembrolizumab in relapsed…Eribulin/ PembrolizumabDr. Amit OzaPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.